
Aerie Pharmaceuticals AERI
Quartalsbericht 2022-Q3
hinzugefügt 23.12.2023
Aerie Pharmaceuticals Betriebsaufwand 2011-2026 | AERI
Betriebsaufwand Jährlich Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 213 M | 253 M | 233 M | 146 M | 96.9 M | 75.1 M | 50 M | 22.2 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 253 M | 22.2 M | 136 M |
Betriebsaufwand Vierteljährlich Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.8 M | 60.3 M | 32.2 M | 27.8 M | 25.4 M | 28.8 M | 23.3 M | 22.7 M | 22.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 60.3 M | 22.1 M | 31.5 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.66 | -0.56 % | $ 1.4 B | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.28 | 7.8 % | $ 138 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 13.4 | -3.67 % | $ 686 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.48 | -0.09 % | $ 2.04 B | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.65 | -0.3 % | $ 3.37 M | ||
|
Evolus
EOLS
|
107 M | $ 5.72 | 0.97 % | $ 355 M | ||
|
Harrow Health
HROW
|
90.1 M | $ 50.59 | -0.81 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 1.39 | 2.21 % | $ 24.3 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.74 | 3.57 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
4.96 B | $ 7.81 | -1.2 % | $ 2.85 B | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.78 | -7.96 % | $ 67.2 M | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
183 M | $ 4.25 | 0.12 % | $ 86.3 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 4.25 | -1.28 % | $ 560 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 26.09 | 0.35 % | $ 1.21 B | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
1.43 B | $ 14.84 | 1.64 % | $ 2.04 B | ||
|
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 1.0 | 4.65 % | $ 23.3 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 4.4 | 1.85 % | $ 132 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.82 | 1.33 % | $ 4.74 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
133 M | $ 9.4 | -0.32 % | $ 668 M | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 5.32 | -5.17 % | $ 217 M | ||
|
Tilray
TLRY
|
1.52 B | $ 9.13 | 1.57 % | $ 5.64 B | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.67 | 3.96 % | $ 32.1 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
44 M | $ 2.32 | -2.11 % | $ 313 M | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 2.01 | -1.62 % | $ 21 M | ||
|
cbdMD
YCBD
|
28.9 M | $ 1.1 | - | $ 4.74 M | ||
|
Viatris
VTRS
|
4.88 B | $ 12.61 | 1.16 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M |